Neuro - Parkinson's disease Flashcards

1
Q

What are the symptoms of PD?

A
Akinetic-rigid syndrome
Loss of movement
Increased muscle tone
Bradykinesia (slow movement)
Rigidity
Resting tremor
Lack of ability to initiate movement
Loss pigmented neuromelanin containing neurones of the subsrantia nigra
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the direct and indirect pathway

A

Direct pathway:
GABAnergic projection from the striatum to the GPi

Indirect pathway:
Projects from the striatum to the GPi via GABAnergic neurones in the GPe and Glutaminergic neurones in the subthalamic nucleus (STN)

The neurones in the GPi are mainly GABAnergic and have an inhibitory influence on the VA-VL in the thalamus which project onto the motor cortex. This inhibitory output from the GPi is believed to restrain thalamocortical motor activity.

Under normal conditions the dopaminergic neurones in the substantia nigra supply the striatum with dopamine which stimulates D1 receptors (direct) and inhibits D2 receptors (indirect). The net result is reduced inhibitory output from the GPi acting on the thalamocortical motor circuit resulting in general facilitation of motor function.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What happens the PD pathway in the brain?

A

Loose the dopaminergic neurons in the substantia nigra and get decreased dopamine therefore decreased stimulation of D1 and D2 receptors leading to decreased activity of the direct pathway and facilitation of the indirect pathway which the net result is increased inhibitory output from the GPi resulting in decreased thalamocortical motor facilitation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Where do you get cell loss in PD?

A

Substantia nigra mainly but also locus ceruleus, dorsal motor nucleus of the vagus, raphe nuclei and nucleus basalis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are Lewy bodies?

A

Spherical intracellular inclusion bodies composed of filamentous and granular material. Have an eosinophilic core and a pale halo. Made up of lots of different proteins but one of the main components is alpha-synuclein. Also contain lipids and Ubiquitin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How many genes have been found to give rise to PD?

A

At least 15 genes have found to be mutated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Which are the four genes focussed on?

A

PARK1/4 - SNCA (alpha-synuclein)
PARK2 - Parkin
PARK5 - UCHL-1
PARK8 - LRRK2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Can we use the familial forms of PD to inform us of the sporadic forms?

A

Yes as they have similar features - can tell us about them and inform us of potential drug targets

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Where is alpha-synuclein present?

A

Presynaptic terminals

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Describe alpha-synuclein

A

140aa protein found in presynaptic terminals
No clear function but involved in synaptic plasticity? Membrane trafficking and vesicle sorting?
Mutations in it can cause PD and gene replication can cause PD
Aggregable and also found in AD plaques

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is LRRK2?

A

LRRK2 - Leucine-rich repeat kinase 2 - complex protein of the ROCO family.

Mutations in this gene have been linked to familial forms of PD with the most common mutation being G2019S.
LRRK2 contains a MAPKKK (kinase effector domain) and ROC-COR domain (GTP binding regulatory domain).

The most common mutation is found in the MAPKKK domain and is part of a highly conserved DYG motif.

PD mutants of LRRK2 increase kinase activity leading to neuronal death.

LRRK2 is a GTP/GDP regulated protein kianse.

Mutations can cause P of its targets without regulation and in rats with was shown that LRRK2 mutants cause less neuronal branching and outgrowth.

Immunohistochemical staining for LRRK2 showed reduction of LRRK2 compared to a control patient.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Describe Parkin

A

Parkin is a 465aa Ub ligase enzyme
Can bind Ub and alpha-synuclein and Ub it for degradation
Was found by mutations
Under normal conditions it was found to be protective targeting excess alpha-syn to the proteosome
Can be found in lewy bodies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What happens if you remove the parkin gene?

A

Get a build up of alpha-syn in the cell which then leads to aggregation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How was Parkin shown to be protective?

A

Stained dopaminergic neurons red
Injecting one side and using the other side as a control
Overexpression of alpha-syn see a reduction in the number of dopaminergic neurones where as overexpression of Parkin see little loss of dopaminergic neurones. Expressing both together you get recovery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is UCHL-1?

A
A de-Ub enzyme -before the protein has to be broken down the Ub has to be removed and UCHL-1 does this by removing Ub at the C-terminal bond
Mutations cause PD or a PD-like syndrome
It is a loss of function mutation
Present in Lewy bodies
Get decrease de-Ub activity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the treatments of PD?

A
Autologous graft neural transplantation
Fetal neuronal transplantation
Stem cell transplantation
Deep brain stimulation
Gene therapy
Growth factors
17
Q

Fetal neuronal transplantation

A

Take the SN (dopamine-containing neurons) from aborted fetus and implant into the patient at caudate nucleus
Good improvements in motor symptoms but side effects of dyskinesia (uncontrolled movements)
Better outcome in younger patients and less severe patients
Trials currently discontinued - ethical issues requiring 6-8 fetus as 90% of the cells die also technical issues and immunosuppresion is needed

18
Q

Autologous graft neural transplantation

A

Take the cells from the patient and transplant them back into the same patient
Adenoidal chromatin cells (release dopamine) into striatum
Reduces rejection and immunosuppression as it is from the same patient
Not really used anymore as adverse psychiatric effects

19
Q

Stem cell transplant

A

Can take stem cells from either a different organism or the patient and induce them to start releasing dopamine
Stem cells induced to differentiate to DA neurons
Transplanted into animal models but problems with getting the stem cells to stop dividing so effectively creates a tumor
No clinical trials yet

20
Q

Deep brain stimulation

A

Electrodes advanced into subthalamic nucleus
Tell it is in the right place by measuring neuronal activity as pushing the electrodes in or measure the tremor of the patient
Quite successful
Pacemaker under the chest to allow patient to control the stimulation
Works quickly
Tends to be used in younger patients because better for surgery

21
Q

Gene therapy

A
Problems with getting the gene to a specific area of the brain also hard to cross BBB
Can combine with transplantation
Varying success in animal models
Genes which could be used:
Parkin
Tyrosine hydroxylase
Anything involved in dopamine expression
22
Q

Growth factors

A

Infusion by catheter as cannot cross BBB - Intracerebroventricular or intraputanimal
Growth factors will increase neuronal sprouting and neuronal growth
GDNF infusion - disappointing
Neurturin gene therapy approach
GDF5 - preclinical development